Hereditary Pancreatic Cancer: Advances in Genetic Testing, Early Detection Strategies, and Personalized Management

Area of Science:

• Oncology
• Genetics
• Cancer Research

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with poor survival rates.
• Approximately 25% of PDAC cases have hereditary or familial predispositions.
• Understanding hereditary pancreatic cancer is critical for improving patient outcomes.

Purpose of the Study:

• To synthesize recent advancements in understanding, detecting, and managing hereditary pancreatic cancer.
• To highlight the role of genetic testing in identifying high-risk individuals.
• To discuss emerging early detection strategies and personalized treatment approaches.

Main Methods:

• Review of recent advancements in hereditary pancreatic cancer research.
• Analysis of the impact of genetic testing (GT) and next-generation sequencing (NGS) panels.
• Evaluation of early detection strategies like miRNA signatures and advanced imaging (e.g., hyperpolarized 13C-MRS).

Main Results:

• Germline pathogenic variants (PVs) are found in up to 20% of hereditary PDAC cases.
• Next-generation sequencing (NGS) has significantly enhanced detection capabilities.
• Identification of germline PVs in homologous recombination (HR) genes predicts treatment response and improves survival.

Conclusions:

• Universal germline testing for PDAC is a standard practice for identifying at-risk individuals.
• Multidisciplinary management integrating genetic counseling and advanced diagnostics is essential.
• Advances in genetic testing and biomarkers are transforming hereditary PC management, emphasizing early detection and personalized therapy.